To determine the incidence and risk factors of immediate hypersensitivity reactions to gadolinium-based magnetic resonance (MR) contrast agents.
Results:
A total of 112 immediate hypersensitivity reactions (0.079% of 141 623 total doses) were identified in 102 patients (0.121% of 84 367 total patients). Among the six evaluated MR contrast media, gadodiamide had the lowest rate (0.013%) of immediate hypersensitivity reactions, while gadobenate dimeglumine had the highest rate (0.22%). The rate for immediate hypersensitivity reactions was significantly higher in female patients (odds ratio = 1.687; 95% confidence interval: 1.143, 2.491) and in patients with allergies and asthma (odds ratio = 2.829; 95% confidence interval: 1.427, 5.610). Patients with a previous history of immediate hypersensitivity reactions had a higher rate of recurrence after reexposure to MR contrast media (30%) compared with the incidence rate in total patients (P , .0001). The incidence of immediate hypersensitivity reactions increased depending on the number of times patients were exposed to MR contrast media (P for trend = .036). The most common symptom was urticaria (91.1%), and anaphylaxis occurred in 11 cases (9.8%). The mortality rate was 0.0007% because of one fatality.
Conclusion:
The incidence of immediate hypersensitivity reactions to MR contrast media was 0.079%, and the recurrence rate of hypersensitivity reactions was 30% in patients with previous reactions. CONTRAST MEDIA: Hypersensitivity to Contrast Media Jung et al physician at the time an adverse reaction begins. In addition, the exact mechanism and risk factors of hypersensitivity reactions are unknown. To protect patients from the potential risk of immediate hypersensitivity reactions to MR contrast media, more detailed studies based on large clinical data sets are necessary. The purpose of this study was to investigate the incidence and risk factors of immediate hypersensitivity reactions to gadolinium-based MR contrast agents.
Materials and Methods

Study Subjects
This study was approved by the institutional review board of Seoul National University Hospital, and informed consent was waived. All cases that used gadolinium-based MR contrast media for MR imaging at Seoul National University Hospital between August 1, 2004 , and July 31, 2010, were reviewed. The demographic data, comorbid disease data, and prescribed medication data were extracted from the electronic medical record. To retrieve data on immediate hypersensitivity reactions, all medical records written by physicians, nurses, and radiology technicians were searched with terms possibly related to immediate hypersensitivity reactions, such as pruritus, skin rash, and urticarial, and with terms for respiratory symptoms. The medical records contained According to studies on the adverse reactions to MR contrast media, the rate of incidence for acute adverse reactions after injection of MR contrast media varied from 0.17% to 2.4% (9) . This is much lower than the rate of incidence for acute adverse reactions associated with low-osmolar nonionic iodinated contrast media used for CT scans, and MR gadolinium-based contrast agents are considered relatively safe (1, 7, 8, 12) .
Adverse events after injection of the contrast media can be divided into three different types: toxic reactions, immediate hypersensitivity reactions, and events unrelated to the exposure of contrast material itself such as a vasovagal reaction (13) . Immediate hypersensitivity reactions occur within 1 hour after administration of the contrast media. Although the most common immediate hypersensitivity symptoms are mild pruritus and urticaria, more severe reactions involving the cardiovascular and respiratory systems can occur (14) . Most previous studies have included all types of adverse reactions other than immediate hypersensitivity reactions. Until now, there have been few studies on the incidence and risk factors of immediate hypersensitivity reactions to MR contrast media (1, 12) .
It is almost impossible to predict which patients are more susceptible to acute adverse reactions to MR contrast media, and recognizing adverse reactions is relatively difficult because patients are positioned for a considerable time inside the bore of an MR imager, which is physically remote from the technologist or supervising D uring the past 3 decades, magnetic resonance (MR) contrast media have been recognized to have superb safety profiles with almost no side effects. Therefore, MR imaging has been routinely used as a safe alternative modality to computed tomographic (CT) scans in patients with hypersensitivity to CT contrast media (1) . However, nephrogenic systemic fibrosis due to MR contrast media has been reported (2, 3) . Cases of severe immediate hypersensitivity reactions such as anaphylaxis to MR contrast media also have been reported (4) (5) (6) . Because the use of MR imaging has increased, several investigations on the safety of MR contrast media have been done (1, (7) (8) (9) (10) (11) .
Implication for Patient Care
n The recurrence reactions occurred in 30% of patients who previously had immediate hypersensitivity reactions to MR contrast media; therefore, the appropriate premedication with antihistamine or systemic corticosteroid should be considered according to the severity of the previous hypersensitivity reactions.
Advances in Knowledge
n The incidence of immediate hypersensitivity reactions to MR contrast media was 0.079% per dose and 0.121% per person.
n The recurrence rate of immediate hypersensitivity reactions to gadolinium-based MR contrast media was 30% (eight of 27) in patients who previously had immediate hypersensitivity reactions to MR contrast media.
n The risk factors for immediate hypersensitivity reactions to MR contrast media in our study were the female sex (odds ratio = 1.687; 95% confidence interval: 1.143, 2.491) and allergies and asthma (odds ratio = 2.829; 95% confidence interval: 1.427, 5.610).
n The incidence of immediate hypersensitivity reactions increased depending on the number of exposures to MR contrast media (0.105%, 0.137%, and 0.171% for one, two, and three or more exposures, respectively).
n Among the six evaluated MR contrast media, gadodiamide had the lowest rate (0.013%) of immediate hypersensitivity reactions, while gadobenate dimeglumine had the highest rate (0.22%).
CONTRAST MEDIA: Hypersensitivity to Contrast Media Jung et al
The severity of the hypersensitivity reactions was classified into three categories by following the guidelines in ACR Manual on Contrast Media (18) . A mild reaction was self-limited with signs and symptoms showing no evidence of progression and included simple rashes, hives, coughing, and swelling of the eyes and face. A moderate reaction had more pronounced symptoms to a moderate degree and included bronchospasm, laryngeal edema, and generalized erythema. A severe reaction was life threatening and included severe laryngeal edema, convulsions, profound hypotension, unresponsiveness, arrhythmia, and cardiopulmonary arrest. Diagnosis of anaphylaxis was made according to the international diagnostic criteria updated in 2006 (19) . Anaphylaxis was defined as a rapid onset, severe, potentially fatal, systemic allergic reaction after exposure to MR contrast media with any one of the following three
Definition of Immediate Hypersensitivity Reactions to MR Contrast Media
Immediate hypersensitivity reactions were defined as cases in which allergy-like symptom(s), such as urticaria, angioedema, bronchospasm, and anaphylaxis, developed within 1 hour after injection of the contrast media. Simple nausea, vomiting, sweating, warmth, anxiety, and reactions involving the site of injection such as pain and burning sensations were excluded when they were not accompanied by other symptoms that suggested immediate hypersensitivity reactions. Reported hypersensitivity symptoms were assessed by two allergy specialists on the basis of the World Health Organization-Uppsala Monitoring Centre causality assessment algorithm (16, 17) . Cases evaluated as certain or probable were considered to have a causal relationship with the administered MR contrast medium. the onset, signs, symptoms, and management, including medications prescribed when immediate hypersensitivity reactions developed. The screened data were first intensively reviewed by two adverse-reaction monitoring nurses and then confirmed by two allergist physicians (S.H.C. and H.R.K., with 18 and 9 years of experience in the field of allergy, respectively).
Demographic data on the study population were collected, including age, sex, and comorbidity, on the basis of the International Classification of Diseases, 10th Revision. In addition, the latest laboratory results such as white blood cell and eosinophil counts, alanine aminotransferase level, and creatinine level within 1 month before exposure to each MR contrast agent were collected. To evaluate renal function, the estimated glomerular filtration rate was determined by using the Modification of Diet in Renal Disease Study method (15) .
In patients with hypersensitivity reactions, data on premedication administered on the day of the reexposure to MR contrast media were extracted. In addition, the medical records of 500 randomly selected subjects from the group without immediate hypersensitivity reactions were screened about premedication. To determine the previous history of exposure to MR contrast media before the study period, data from January 2000 to July 2004 were also searched, and the number of exposures to MR contrast media and the different kinds of MR contrast media that a patient was exposed to were reviewed (Fig 1) .
The following gadolinium-based contrast media were utilized: (a) macrocyclic agents including ionic gadoteric acid (Dotarem; Guerbet, Roissy, France) and nonionic gadobutrol (Gadovist; Bayer Schering Pharma, Berlin, Germany) and (b) linear agents including ionic agents gadopentetate dimeglumine (Magnevist; Bayer Schering Pharma), gadobenate dimeglumine (MultiHance; Bracco Diagnostics, Milan, Italy), and gadoxetic acid (Primovist; Bayer Schering Pharma) and the nonionic agent gadodiamide (Omniscan; GE Healthcare, Oslo, Norway). and 35 [0.071%] of 49 201 in nonionic agents). Among the linear agents, ionic agents had a higher incidence of immediate hypersensitivity reactions than nonionic agents (0.085% vs 0.013%, P = .0004), but the presence or absence of ionicity did not affect the incidence rate among the macrocyclic agents.
The proportion of subjects exposed to gadobenate dimeglumine was significantly higher and the proportion of subjects exposed to gadodiamide was significantly lower in the immediate hypersensitivity reactions group than in the group without immediate hypersensitivity reactions (Table 1) .
Clinical Characteristics
The incidence of immediate hypersensitivity reactions was 0.098% in women (73 of 74 066), which was almost double the rate in men (39 [0.058%] of 67 557, P = .006) ( Table 1 ). The proportion of female patients was significantly higher in the group with immediate hypersensitivity reactions than in the group without immediate hypersensitivity reactions (65.2% vs 52.3%, P = .006). The mean age was not different between the two groups. Laboratory data were available in 121 395 patients (85.7%). There was no significant difference in total white blood cell and
The numbers of exposures to MR contrast media varied from one to 54, and the mean was 1.7 exposures per person. A total of 72.2% of the study subjects (60 925) were exposed to gadolinium-based contrast media only one time.
There were 148 acute reactions, of which 36 cases of vomiting, nausea, and pain at the injection site were excluded. The incidence of immediate hypersensitivity reactions was 0.079% (112 of 141 623) (Fig 2) 
Statistical Analysis
Software (SPSS, version 17.0; SPSS, Chicago, Ill) was used for statistical analysis. The analyzed items are summarized in Figure 1 . The incidence of immediate hypersensitivity reactions to MR contrast media was calculated. To compare the hypersensitivity reaction group to the group without hypersensitivity reaction, the x 2 test, Fisher exact test, and Student t test were used. To evaluate the trend for the male proportion according to the severity and the incidence of immediate hypersensitivity reactions according to the number of exposures to MR contrast media, the x 2 test for trend was used. To compare the parameters according to the severity of the immediate hypersensitivity reactions, the analysis of variance test was used. Multiple logistic regression analysis for sex, age, allergic disease, type of MR contrast media, and number of previous exposures to MR contrast media was performed to identify the risk factors related to immediate hypersensitivity reactions to MR contrast agents, and the results were presented as odds ratios and 95% confidence intervals. A P value less than .05 was considered to indicate a significant difference. Graph shows incidence of immediate hypersensitivity reactions to MR contrast media, which was 0.079% of the total doses administered. Gadobenate dimeglumine had the highest rate of incidence (0.22%), and gadodiamide had the lowest (0.013%). * = ionic agent, † = nonionic agent.
Results
Incidence of Immediate Hypersensitivity Reactions to MR Contrast Media
CONTRAST MEDIA: Hypersensitivity to Contrast Media
Jung et al contrast media-induced anaphylaxis, anaphylaxis recurred when he was exposed to a different MR contrast material, with antihistamine as a premedication 51 days after his first anaphylactic episode.
In six of 11 cases, low blood pressure was quickly recovered with only prompt massive hydration. Three of the 11 cases of anaphylaxis were treated with epinephrine, and two cases were managed with other vasopressors such as dopamine and norepinephrine. In addition, four patients with respiratory distress were treated with b 2 agonist inhalation.
In the 102 patients who had immediate hypersensitivity reactions for the first time, more than half of the patients (60 patients, 58.8%) had hypersensitivity symptoms at their first exposure to MR contrast media. However, 42 patients (41.2%) had already been exposed to MR contrast media before the development of immediate hypersensitivity reactions, including 28 patients (27.5%) who had been exposed to exactly the same MR contrast agent. Chart review showed that premedication such as antihistamine or systemic steroid was not administered odds ratio = 0.122; 95% confidence interval: 0.029, 0.520).
Symptoms
Among the 112 hypersensitivity reactions, urticaria was the most common symptom observed in 102 cases (91.1%). Respiratory symptoms occurred in seventeen cases (15.2%); hypotension was observed in 11 cases (9.8%), and angioedema was observed in six cases (5.4%). Nineteen cases (17.0%) had multiple symptoms.
Eleven severe hypersensitivity reactions occurred in 10 patients, and all of them met the diagnostic criteria for anaphylaxis. Detailed clinical characteristics of each case of anaphylaxis are presented in Table E1 (online). Hypotension was present in all cases, respiratory symptoms in 10 cases (91%), and cutaneous manifestations in seven cases (64%).
One fatality occurred in a 76-yearold woman who developed the following symptoms: hypotension, dyspnea, nausea, and decreased consciousness after gadobutrol injection, and she died despite prompt cardiopulmonary resuscitation. The mortality rate was 0.0007%. In a patient who had experienced MR eosinophil counts, alanine aminotransferase level, and creatinine level between the two groups. There was no significant difference in the number of previous exposures to MR contrast media or in the number of previous exposures to a specific type of contrast media between the two groups.
In terms of underlying diseases, the presence of hypertension and diabetes did not affect the incidence of immediate hypersensitivity reactions (P = .468 and .842, respectively). However, allergic diseases such as asthma, allergic rhinitis, chronic urticaria, food allergies, and drug hypersensitivity were more frequent in the group with immediate hypersensitivity reactions than in the group without immediate hypersensitivity reactions (P = .002) ( Table 2) .
Multiple logistic regression analysis showed significant results for female sex (P = .009; odds ratio = 1.687; 95% confidence interval: 1.143, 2.491), allergies and asthma (P = .003; odds ratio = 2.829; 95% confidence interval: 1.427, 5.610), gadobenate dimeglumine (P = .0002; odds ratio = 3.003; 95% confidence interval: 1.701, 5.303), and gadodiamide (P = .004; CONTRAST MEDIA: Hypersensitivity to Contrast Media Jung et al not different between the recurrence group and nonrecurrence group. Recurrence was not related to the kind of contrast media. The recurrence rates were 23.8% (five of 21) and 27% (three of 11) when exposed to the same or different contrast agents, respectively (P = .575). Among the 27 patients who experienced immediate hypersensitivity reactions and were reexposed to MR contrast media, 11 patients were premedicated with antihistamine or corticosteroid and four (36%) had recurrent immediate hypersensitivity reactions. Among the 16 patients without premedication, four patients (25%) experienced recurrent immediate hypersensitivity reactions. There was no difference in the recurrence rate of the immediate hypersensitivity reactions according to premedication (P = .414).
The timing of recurrence varied. While six of 27 (22%) patients experienced recurrence at their second exposure after the exposure resulting in immediate hypersensitivity reactions, two of 16 (13%) eventually experienced recurrence at their third exposure without any reaction after their second exposure after the exposure resulting in immediate hypersensitivity reactions. One of seven (14%) reexperienced immediate hypersensitivity reactions at their fourth exposure, and one of eight (13%) reexperienced immediate hypersensitivity reactions during five or more reexposures after the initial immediate hypersensitivity reaction (Fig 4) .
Discussion
To our knowledge, this study involved the largest number of subjects who had gadolinium-based MR contrast media administered at a single hospital to date, and it is the first study that included detailed demographic data on the subjects.
Although the incidence of immediate hypersensitivity reactions to MR contrast media in our study was similar to the results of a previous study (0.079% vs 0.07%) (1), when the incidence per person was calculated, the rate went up to 0.121%.
Frequency of MR Contrast Media Exposure and Incidence of Immediate Hypersensitivity Reactions to MR Contrast Media
The incidence of immediate hypersensitivity reactions was 0.105% (61 of 57 966 patients) for one exposure, 0.137% (17 of 12 381 patients) for two exposures, and 0.171% (24 of 14 020 patients) when exposed three times or more (P for trend = .036). This trend was maintained in patients with a mild reaction (P for trend = .017) but not in patients with moderate or severe reactions (Fig 3) .
In patients who had previous immediate hypersensitivity reactions, the overall recurrence rate of immediate hypersensitivity reactions to the MR contrast media was 30% (eight of 27), and it was markedly higher than the incidence in total patients (0.121%, P , .0001). Among 10 cases with recurrent hypersensitivity reactions, six patients experienced one recurrent reaction and two patients experienced two recurrent reactions.
Among the 27 patients with known immediate hypersensitivity reactions who were reexposed to MR contrast media after previous immediate hypersensitivity reactions, age (54 years vs 49 years), sex (female, 50% vs 47.4%), allergies and asthma (25% vs 5.3%), number of previous exposures to MR contrast media (2.13 vs 3.21), and the time interval between the immediate hypersensitivity reactions and reexposure (189.63 days vs 266.05 days) were when hypersensitivity reactions developed for the first time. No one was premedicated before the administration of MR contrast media in subjects selected from the group without immediate hypersensitivity reactions.
Clinical Characteristics according to Immediate Hypersensitivity Reaction Severity
Mild reactions (83.0%) were predominant, followed by severe and moderate reactions at the rate of 9.8% and 7.1%, respectively ( Table 3 ). The incidence of mild, moderate, and severe reactions was 0.066%, 0.006%, and 0.008%, respectively.
The proportion of male patients experiencing immediate hypersensitivity reactions increased as the severity of the reactions increased (29.0%, 50.0%, and 72.7% in the order of mild, moderate, and severe reaction, respectively), and a linear trend was observed according to the severity (P for trend = .003). The incidence of severe immediate hypersensitivity reactions was three times higher in men (0.012%) than in women (0.004%) (Table 4) .
However, age, underlying diseases, leukocyte counts, use of b-blockers, and use of different kinds of contrast media did not have any significant effect on the severity of the immediate hypersensitivity reactions. Creatinine levels were within normal range, and the estimated glomerular filtration rates were not different among the three groups for severity. experienced immediate hypersensitivity reactions, and it was remarkably higher than the general incidence rate of 0.079%. Prince et al (11) reported that patients who experienced adverse events had a higher incidence of prior reactions to gadolinium-based agents, and the American College of Radiology Committee on Drug and Contrast Media recommends that caution should be used for patients who have a history of adverse reactions after injection of MR as occurring twice as frequently in patients with allergies or asthma (22, 23) . In our study, the frequency of underlying allergic diseases was three times as high in the group with immediate hypersensitivity reactions compared with the group without any immediate hypersensitivity reactions. One notable result was that the overall recurrence rate of immediate hypersensitivity reactions was as high as 30% in patients who previously Although most immediate hypersensitivity reactions were mild and urticaria was the most common symptom in our study, the incidence of moderate and severe reactions together was 0.013% per MR contrast media dose and 0.021% per person, which was rare but not low enough to be ignored.
Currently, little is known about the risk factors associated with the development of immediate hypersensitivity reactions to MR contrast agents. We reconfirmed the female predominance in immediate hypersensitivity reaction to MR contrast agents reported in previous studies (1, 11) and reported the susceptibility of male patients to the severe type of immediate hypersensitivity reactions to MR contrast agents.
In prior reports, immediate hypersensitivity reactions to MR contrast media were 2.3 to 3.7 times more likely in patients with allergies or asthma (20, 21) . This tendency is similar to that of iodinated contrast media, where hypersensitivity reactions were reported (11) . In our study, there was one fatality, which translated to a mortality rate of 0.0007%. In the case of immediate hypersensitivity reactions to MR contrast media, the pathophysiologic mechanism is largely unknown. However, some reports suggest the role of an immunoglobulin E-mediated reaction in MR contrast media-related hypersensitivity (24, 25) . These investigators observed positive skin reactions to the MR contrast media that caused anaphylaxis. However, it is still unclear whether polysensitization and cross-reaction exist within similar molecules. Another report suggesting an immunologic mechanism revealed that the risk of immediate hypersensitivity reactions was increased up to eight times if patients had a history of hypersensitivity to MR contrast media, with the second reaction tending to be more severe than the first one (21) . In our study, the overall recurrence rate after reexposure to MR contrast agent was up to 30%, and the more frequently exposed group had a higher incidence rate. To evaluate the role of the immunologic mechanism in hypersensitivity induced by MR contrast media, a skin test with MR contrast media that causes immediate hypersensitivity reactions is needed.
Our study had limitations that are associated with any retrospective study. All the medications prescribed before each MR contrast media exposure were retrieved electronically and manually reviewed to validate premedication in the group with immediate hypersensitivity reactions. This process was not performed in the group without immediate hypersensitivity reactions because of the difficulty involved and the low likelihood of premedication being routinely prescribed for MR contrast media in practice. Instead of a thorough review for premedication, we
In that study, the rates of acute adverse reactions to gadobenate dimeglumine and gadodiamide were 0.12% and 0.02%, respectively (11) .
We found that the mean creatinine levels were higher in patients with more severe immediate hypersensitivity reactions; however, the mean creatinine level values were within the normal range for all subgroups. Moreover, the estimated glomerular filtration rate was not significantly different according to the severity of the immediate hypersensitivity reactions. Thus, the effect of renal function on the development of immediate hypersensitivity reactions is uncertain.
We found that the rate of incidence for anaphylaxis was 0.008%, which was similar to previously reported rates of contrast media; premedication should be administered to patients who had a previous moderate or severe reaction (18) . In our study, of the 41% of patients with previous immediate hypersensitivity reactions to MR contrast media who received premedication, 64% of the patients had no subsequent immediate hypersensitivity reactions.
In our study, gadobenate dimeglumine had the highest incidence of immediate hypersensitivity reactions (0.22%), while gadodiamide had the lowest incidence (0.013%). Our results were similar to those of a recently published study (11) , which reported a substantially higher adverse reaction rate to gadobenate dimeglumine and gadopentetate compared with gadodiamide. Graph shows recurrence rate and timing of immediate hypersensitivity reactions to gadolinium-based MR contrast media in patients with previous immediate hypersensitivity reactions. The overall recurrence rate of immediate hypersensitivity reactions to MR contrast media was 30% in patients who previously had a hypersensitivity reaction to MR contrast media.
CONTRAST MEDIA: Hypersensitivity to Contrast Media Jung et al screened the medical records of 500 randomly selected subjects from the group without immediate hypersensitivity reactions, and no one was premedicated before the administration of MR contrast media. Therefore, the possibility of underestimation of the immediate hypersensitivity reaction because of premedication seems to be very low.
Another limitation was that the doses of gadolinium-based MR contrast media given to each patient were not clearly defined. In addition, information on exposure to MR contrast media before January 2000 was not complete, and exposures at other institutions were not obtained.
For more precise analyses on the clinical features and pathogenic mechanisms related to MR contrast mediainduced immediate hypersensitivity reactions, large-scale prospective studies including in vivo and in vitro allergy tests are needed.
In summary, in our study, MR contrast media induced immediate hypersensitivity reactions at an incidence rate of 0.079%. The risk factors for immediate hypersensitivity reactions include the female sex, underlying allergic diseases, multiple exposures, and a previous history of hypersensitivity to MR contrast media. The recurrence rate of immediate hypersensitivity reactions was 30% in patients who previously experienced hypersensitivity reactions. Therefore, premedication should be considered for patients who had previous immediate hypersensitivity reactions. 
